Valuation: Proteomics International Laboratories Ltd

Market Cap 21.5M 15.32M 13.34M 12.59M 11.43M 21.42M 1.47B 150M 58.2M 747M 57.51M 56.23M 2.4B P/E 2025
-5.38x
P/E 2026 -1.8x
Enterprise Value 18.33M 13.06M 11.37M 10.73M 9.74M 18.26M 1.25B 128M 49.63M 637M 49.03M 47.95M 2.05B EV / Sales 2025
12.8x
EV / Sales 2026 4.7x
Free-Float
73.39%
Yield 2025 *
-
Yield 2026 -
1 day-7.14%
1 week-7.14%
Current month-13.33%
1 month-18.75%
3 months+13.04%
6 months-55.93%
Current year-80.15%
1 week 0.13
Extreme 0.13
0.14
1 month 0.13
Extreme 0.13
0.17
Current year 0.1
Extreme 0.098
0.86
1 year 0.1
Extreme 0.098
0.86
3 years 0.1
Extreme 0.098
1.4
5 years 0.1
Extreme 0.098
1.4
10 years 0.1
Extreme 0.098
1.48
Manager TitleAgeSince
Chief Executive Officer - 19/01/2026
Director of Finance/CFO - 17/04/2026
Director of Finance/CFO - 12/07/2021
Director TitleAgeSince
Director/Board Member - 22/11/2017
Chairman 56 -
Director/Board Member - 08/11/2024
Date Insider Type Main position Quantity % Market Cap. Importance
21/11/24 Free

Founder

800,000 0.6107%
21/11/24 Free

Founder

800,000 0.6107%
21/11/24 Free

Founder

1,000,000 0.7633%
Change 5-day change 1-year change 3-year change Capi.($)
-7.14%-7.14%-62.86%-85.56% 15.28M
-0.31%+5.79%+47.13%+99.00% 70.88B
+0.39%+2.06%+39.38%+78.27% 62.49B
+0.50%+7.13%+33.27%+16.01% 26.34B
-3.21%-7.27%-17.10%+356.10% 26.21B
-2.64%-0.69%-0.17%-13.01% 24.13B
+0.71%+8.03%+25.03%-12.74% 20.72B
+2.12%-5.86%+161.58%+329.34% 15.36B
-0.22%+3.99%+45.54%+172.46% 14.46B
+0.73%+1.71%-5.51%+849.47% 14.24B
Average -0.91%+1.57%+26.63%+178.93% 27.48B
Weighted average by Cap. -0.28%+1.49%+35.68%+148.21%

Financials

2025 2026
Net sales 3.31M 2.36M 2.05M 1.94M 1.76M 3.3M 226M 23.16M 8.97M 115M 8.86M 8.66M 370M 3.37M 2.4M 2.09M 1.97M 1.79M 3.36M 230M 23.57M 9.12M 117M 9.02M 8.82M 377M
Net income -8.11M -5.78M -5.03M -4.75M -4.31M -8.09M -554M -56.74M -21.97M -282M -21.71M -21.23M -907M -8.56M -6.1M -5.31M -5.01M -4.55M -8.53M -584M -59.86M -23.17M -298M -22.9M -22.39M -957M
Net Debt -10.76M -7.66M -6.67M -6.3M -5.72M -10.72M -735M -75.24M -29.13M -374M -28.78M -28.14M -1.2B -3.17M -2.26M -1.97M -1.86M -1.68M -3.16M -216M -22.16M -8.58M -110M -8.48M -8.29M -354M
Logo Proteomics International Laboratories Ltd
Proteomics International Laboratories Ltd is an Australia-based medical technology company. The Company is engaged in predictive diagnostics and bioanalytical services. It specializes in the area of proteomics, the industrial scale study of the structure and function of proteins. It focuses on developing and commercializing diagnostic tests for chronic diseases. Its principal activities fall into three key areas: commercialization of PromarkerD, the predictive test for diabetic kidney disease (DKD) and future kidney function decline in patients with type 2 diabetes; precision diagnostic tests in development: the Promarker pipeline, and specialist accredited analytical services on a commercial basis. Its Promarker pipeline and analytical services include PromarkerEndo, PromarkerEso and OxiDx technology. PromarkerEndo is a prototype diagnostic test for endometriosis identifying up to 90% of patients with the disease. PromarkerEso is a prototype diagnostic test for esophageal cancer.
Employees
-
Date Price Change Volume
18/09/26 A$0.1300 -7.14% 169,158
17/09/26 A$0.1400 0.00% 89,709
16/09/26 A$0.1400 +3.70% 31,909
15/09/26 A$0.1350 -3.57% 82,277
14/09/26 A$0.1400 0.00% 113,363

Annual profits - Rate of surprise

-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!